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Synthesis of rigidified shikimic acid derivatives by
ring-closing metathesis to imprint inhibitor
efficacy against shikimate kinase enzyme†
Marina Pernas, a Beatriz Blanco, a Emilio Lence, a Paul Thompson, b
Alastair R. Hawkinsb and Concepción González-Bello *a
Diverse rigidified shikimic acids derivatives, which are stable mimetics of the high-energy conformation of
shikimic acid, have been synthesized to enhance inhibitor efficacy against shikimate kinase enzyme (SK),
an attractive target for antibiotic drug discovery. The synthesis of the reported conformationally restricted
shikimic acid derivatives was carried out by ring-closing metathesis of allyloxy vinyl derivatives as the key
step. The rigidification of the ligand conformation was used to maximize the effectiveness of the substitu-
ents introduced in the ether carbon bridge of the scaffold by pre-orienting their interaction with key resi-
dues and enzyme domains that are essential for catalysis and enzyme motion. Molecular Dynamics simu-
lation studies on the enzyme/ligand complexes revealed marked differences in the positioning of the
ligand substituent in the active site of the two enzymes studied (SK from Mycobacterium tuberculosis and
Helicobacter pylori) and this explains their greater efficacy against one of the enzymes. This enhancement
is due to the distinct induced-fit motion of the two homologous enzymes. A 20-fold improvement
against the H. pylori enzyme was achieved by the introduction of a CH2OEt group in the rigid ether bridge
of the reported shikimic acid analogs.
Introduction
Flexible ligands upon binding to their biological target may
suffer an entropic penalty due to the freezing of their rotatable
bonds to achieve the active binding conformation.1,2 In some
cases these ligands may also adopt high-energy active confor-
mations in order to maximize favorable interactions with the
residues involved in the protein binding pocket.3,4 Hence, pre-
organization of the ligand conformation or stabilization of the
required high-energy active arrangements through the intro-
duction of conformational constraints is a very attractive strat-
egy that is used in drug design.5–9 The rigidification of the
ligand conformation can also be considered as an ‘atom-
efficient approach’, since it maximizes the efficiency of the
functional groups introduced into the initial scaffold during
the drug optimization process as the interactions of those
groups with the binding pocket are well pre-oriented.10–12
We became interested in using this appealing concept in
the development of inhibitors of the fifth enzyme of the shiki-
mic acid pathway, namely the shikimate kinase (SK) enzyme.
SK is an attractive target for antibiotic drug discovery because
(i) it has no counterpart in human cells; and (ii) it is essential
in several very relevant pathogenic bacteria that nowadays
show high levels of resistance to many antibiotics in clinical
use. Specifically, SK is crucial for: (i) Mycobacterium tuberculo-
sis, which is responsible for tuberculosis – a globally estab-
lished Word Health Organization (WHO) priority; (ii)
Helicobacter pylori, which is the causative agent of gastric and
duodenal ulcers and has also been classified as a type I carci-
nogen; and (iii) Pseudomonas aeruginosa, which is one of the
most common pathogens in healthcare-associated infections
and a WHO critical pathogen for R&D of new antibiotics. SK
catalyzes the stereospecific phosphorylation of the C3 hydroxyl
group of shikimic acid (1) by transferring the γ-phosphate
group of ATP to the hydroxyl group to provide shikimate
3-phosphate and ADP (Fig. 1A). This enzyme is an amazing
example of how the specific transformation of only one of
three hydroxyl groups of the ligand is achieved by an exqui-
sitely designed stabilization of its high-energy conformation.
By forcing the axial disposition of the C4 and C5 hydroxyl
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groups in 1, the enzyme achieves the equatorial arrangement
of the C3 hydroxyl group for selective phosphorylation by ATP.
Based on the aforementioned recognition, we reported pre-
viously that the rigidified shikimic acid derivative 2, in which
the conformation that the enzyme recognizes for catalysis is
fixed by an unsaturated ether bridge between positions C3 and
C5 in 1, is a reversible competitive inhibitor of SK from
M. tuberculosis (Mt-SK) (Fig. 1B).13 Compound 2 proved to have
an inhibition constant (Ki) of 62 µM, which is lower than the
enzyme Km (544 µM). The crystal structure of Mt-SK in complex
with ADP and 2 (PDB entry 4BQS, 2.15 Å) revealed that the
ligand occupies the active site with a similar arrangement and
polar interactions (hydrogen bonding and electrostatic inter-
actions) as 1. More importantly, the structure shows that the
rigidification of the diaxial conformation of the C4 and
C5 hydroxyl groups in 1 by a C3–C5 ether bridge causes a dra-
matic reduction in the flexibility of the lid and shikimic acid
binding (SB) domains, the plasticity of which is essential for
catalytic turnover. The SB domain, which involves several
highly conserved lipophilic residues, isolates the substrate
from the solvent environment to perform the reaction.
Molecular Dynamics (MD) simulation studies also revealed
that a closed form of the lid and SB domains are required for
catalysis.13 Moreover, reduction of the double bond of the
C3–C5 ether bridge in 2, to give compound 3, improves the
ligand affinity a little more (Ki = 46 µM) by enhancing lipophi-
lic interactions between the ether bridge and residues of the
lid domain, thus sealing the active site even more.
Based on these results, we report herein the possible
enhancement of the inhibitor efficiency of this scaffold, com-
pound 2, by promoting favorable lipophilic interactions
between the ligand and the lid (Fig. 1C). To this end, we
carried out the synthesis of rigidified shikimic acid derivatives
4–5 in which the closest sp2 carbon of the unsaturated bridge
to the lid was substituted with diverse apolar groups that pre-
orient their interaction with this important part of the
enzyme. In addition, the relevance of the double bond to
ligand affinity was studied with compounds 5. The results of
inhibition studies with the SK from M. tuberculosis and from
H. pylori, along with MD simulation studies on the enzyme/
ligand complexes, allowed us to explain the higher efficacy of
the reported compounds observed for the H. pylori enzyme.
Results and discussion
Synthesis of compounds 4–5
The synthesis of conformationally restricted shikimic acid
derivatives 4–5 was carried out by ring-closing metathesis of
the allyloxy vinyl derivatives 6 as the key step (Fig. 2).
In an effort to facilitate the formation of the seven-mem-
bered bridge ring in 6, the axial arrangement of the vinyl
group in C3 was induced by protecting the hydroxyl groups in
the C3 and C4 positions of the shikimic acid derivative as an
acetal (Fig. S1†). The key compounds 6 were prepared by Trost
allylation of previously reported alcohol 7 13 using the appro-
priate allyl methyl carbonates 8.
Allyl methyl carbonates 8 were prepared from the corres-
ponding alcohols 14–21 by treatment with methyl chlorofor-
mate and pyridine (Scheme 1). Alcohols 15–17 were syn-
thesized by 1,2-reduction of α,β-unsaturated aldehydes 11
(commercially available) and 12–13, with the latter compounds
readily prepared from pentanal (9) and hexanal (10), respect-
ively. Alcohol 18 was obtained in four steps from ethyl malo-
nate (22): (i) alkylation of 22 with cyclopropylmethyl bromide;
(ii) decarboxylative hydrolysis; (iii) aldol condensation; and (iv)
1,2-reduction of α,β-unsaturated acid 23. Alcohols 20–21 were
synthesized by alkylation of commercially available 2-methyl-
ene-1,3-propanodiol (19). Finally, carbonate 8i was obtained by
TBS-protection of carbonate 8h.
Palladium-catalyzed Trost allylation of 7 with allyl methyl
carbonates 8a–g and 8i gave the key intermediates 6a–g and 6i
in yields ranging from 32–88% (Scheme 2 and Table 1). Ring-
closing metathesis of 6a–g and 6i was achieved by using
Fig. 1 A. Schematic representation of shikimic acid (1) recognition by
SK. B. Previously reported reversible competitive inhibitors. C. Target
compounds.
Fig. 2 Synthetic approach.
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second-generation Grubbs’ catalyst in toluene at 90 °C to
afford bicyclic derivatives 24a–g and 24i in yields ranging from
16–63%, and from 42–99% considering the recovered starting
material. Bicyclic derivative 24h was efficiently prepared from
24i by TBS-deprotection with TBAF. As expected, the meta-
thesis reaction proved to be quite sensitive to the presence of
substitution in the allyl moiety, since: (i) when R = H the trans-
formation took place at room temperature and in a higher
yield (88%);13 and (ii) an increase in the steric hindrance of
the substituent led to lower reaction yields and required
higher reaction temperatures (Table 1). Derivatives 24g and
24f, which contained a CH2OBn and a CH2OEt group, respect-
ively, gave the lowest yields. These compounds were alterna-
tively prepared by alkylation of alcohol 24h in 64% and 31%
(57%) yield, respectively. Deprotection of the acetal group in
24, followed by basic hydrolysis of the resulting esters 25a–h
and subsequent protonation with Amberlite IR-120 (H+) ion-
exchange resin efficiently afforded the target compounds 4.
Finally, compounds 5, which have a flexible substituted ether
bridge, were synthesized from methyl derivative 25a by cata-
lytic hydrogenation using Rosenmund catalyst in the presence
of pyridine, followed by hydrolysis of the methyl ester to give a
1 : 1 mixture of epimers in the C4 position, i.e., compounds 5S
and 5R, which were separated by HPLC. The configuration of
the new chiral center was determined by NOE experiments.
Inversion of H10 in bicycles 5S and 5R led to enhancement of
the signals for H4 (3.6%) and the methyl group (5.2%),
respectively.
Inhibition studies
The inhibitory activity of the reported conformationally
restricted shikimic acid derivatives 2–5 was assayed against SK
from Helicobacter pylori (Hp-SK) and from M. tuberculosis
(Mt-SK). All of the compounds proved to be competitive
reversible inhibitors of shikimic acid for both enzymes.
The inhibition data (Ki), which were obtained from Dixon plots
(1/v vs. [I]), are summarized in Table 2.
In general: (i) the ligands proved to be more potent against
the H. pylori enzyme than the M. tuberculosis enzyme; (ii) a
rigid ether bridge between the C3 and C5 positions of shikimic
acid provided more potent inhibitors (Table 2, entries 3 vs. 11);
(iii) for Hp-SK, the inhibition potency of the ligands increased
with the length of the substituent chain (Table 2, entries 5 and
Scheme 1 Synthesis of carbonates 8. Reagents and conditions. (a)
HCHO, pyrrolidine, propionic acid, iPrOH, 45 °C. (b) NaBH4, MeOH,
Et2O, 0 °C to RT. (c) 1. NaH, DMF, 0 °C; 2. EtBr, RT. (d) 1. NaH, THF, 0 °C;
2. BnBr, RT. (e) MeOCOCl, Py, DCM, 0 °C to RT. (f ) 1. NaH, THF, 0 °C; 2.
BrCH2cPr, Δ. (g) NaOH (2 M), Δ. (h) piperidine, HCHO, EtOH, 80 °C. (i)
BH3·Me2S, THF, 0 °C to RT. ( j) TBSCl, DMAP, TBAI, Et3N, DMF, 0 °C to RT.
Table 1 Yields for the conversion 7 → 6 and 6 → 24
R 6 Yielda (%) 24 Yielda (%)
Me 6a 88 24a 63 (77)
Et 6b 32 (74) 24b 47 (97)
nPr 6c 47 24c 63 (89)
nBu 6d 49 24d 54
cPr 6e 34 24e 45 (99)
CH2OEt 6f 54 24f 16 (78)
CH2OBn 6g 63 24g 26 (94)
CH2OTBS 6i 43 24i 42
a Isolated yields. Corrected yields are shown in brackets.
Scheme 2 Synthesis of compounds 4–5. Reagents and conditions. (a)
8a–g and 8i, Pd2(dba)3 (cat), dppb, THF, Δ. (b) 2nd generation Grubbs’
catalyst, PhMe, 90 °C. (c) MeOH, HCl (6 M), 60 °C. (d) TBAF, THF, 0 °C.
(e) 1. NaH, THF, 0 °C; 2. BnBr, RT. (f ) 1. NaH, DMF, 0 °C; 2. EtBr, RT. (g) 1.
LiOH (aq.), THF, RT. 2. Amberlite IR-120 (H+), RT. (h) H2, Rosenmund
catalyst, MeOH, Py. RT.
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8 vs. 1 and 4), while for Mt-SK only the introduction of a
methyl group in the rigid ether bridge improved the inhibitory
activity (Table 2, entries 3 vs. 5); (iv) the presence of a hydroxyl
or an ether group in the substituent only enhanced the inhibi-
tory activity for Hp-SK (Table 2, entries 8 vs. 5).
For the H. pylori enzyme, the best inhibitor in the series
was compound 4f, which has a CH2OEt substituent in the
ether bridge. This enhanced the inhibitory potency by up to
20-fold. For the M. tuberculosis enzyme, a 2-fold improvement
in activity was achieved with compound 4a, which has a
methyl group. Computational studies were performed in an
effort to gain a better understanding at the atomic level of the
differences observed experimentally in the inhibitory potency
of the reported conformationally rigid shikimic acid analogs
4–5. The results of these studies are discussed below.
Computational studies
Molecular docking using the GOLD 5.2.2 14 program and the
protein coordinates found in the crystal structures of Hp-SK in
complex with shikimate-3-phosphate and ADP (PDB entry
3MUF,15 2.3 Å) and of Mt-SK in complex with 2 and ADP (PDB
entry 4BQS,13 2.15 Å) were carried out first. The highest score
solutions obtained by docking were further analyzed by
Molecular Dynamics (MD) simulation studies in order to
assess the stability and therefore the reliability of the postu-
lated binding. The monomer of the Hp-SK/ATP/Mg2+/ligand
and Mt-SK/ATP/Mg2+/ligand complexes in a truncated octa-
hedron of water molecules obtained with the molecular mech-
anics force field AMBER16 was employed and the system was
then subjected to 100 ns of dynamic simulation. The latter was
carried out with the most active ligands, compounds 4a–d and
4f, as well as the analogs with a flexible ether bridge, i.e., 5S
and 5R (Fig. 3).
The results of the computational studies revealed that, in
all cases, the ligands would be stable in the shikimic acid
active site, since significant variations were not observed
during the whole simulation, both in the position of the
ligand and in the protein backbone (Fig. S2 and S3†). As one
would expect, the ligands would be anchored to the active site
by the same electrostatic and polar interactions as the original
compound 2 (Fig. S4†). More importantly, relevant differences
were identified in the arrangement of the substituent of the
ether bridge of the ligands for both enzymes and this would
explain the experimentally obtained activity. Thus, for Hp-SK
and during most of the simulation, these substituents were
mainly embedded in the active site, with both the lid and the
SB domain completely surrounding the entire ligand
(Fig. 3A–F). For compounds 4b–d and 4f (R ≠ H, Me), the per-
centage of conformations with the substituent ‘inside’ the
active site increased as the chain length increased, which is in
good agreement with the observed improvement in the inhibi-
tory potency (CH2OEt > nBu > nPr > Et) (Fig. 3I). These values
were calculated by analyzing the variation of the dihedral
angle between the atoms C5 (CAF), C4 (CAE) and the first two
atoms of the substituent, C (CAP) and C (CAR)/O (OAR), in 4b–
d and 4f during the whole simulation (Fig. S5 and S6†).
‘Substituent inside conformations’ were considered for values
of the dihedral angle between −50° and −150°. As a result of
this arrangement, the shikimic acid active site remained neatly
closed, thus avoiding the entrance of the natural substrate,
because the ligands caused a dramatic reduction in the flexi-
bility of the lid and SB domain by a series of favorable apolar
interactions between the substituent and the residues in this
pocket (Fig. 4A–D). It is worth highlighting that MD studies in
the enzyme product complex, i.e., in the presence of ADP and
shikimate-3-phosphate, revealed that the flexibility of the lid
and the SB domain are key for the catalytic turnover.13 The lid
is the substrate-covering loop that closes over the shikimic
acid binding site for catalysis and it contains the essential
residue Arg116/Arg117 (H. pylori and M. tuberculosis, respect-
ively). NMR studies revealed that this residue might also be
involved in the phosphoryl-transfer mechanism catalyzed by
SK by activating and positioning the reaction intermediate for
subsequent nucleophilic attack by the C3 hydroxyl group
in 1.18 The aforementioned apolar interactions would be more
numerous as the length of the chain increases, which would
explain the enhancement in ligand affinity. In general, these
interactions would involve the residues of the: (i) lid: Arg116
(essential), Pro117 (conserved) and Leu118; (ii) the SB domain:
Val44 and Arg45; and (iii) the P-loop: Met10 (Fig. S7†). For the
most potent inhibitor, compound 4f, an additional interaction
was identified between the oxygen atom of the substituent and
the amide main chain (carbonyl) of Val44 through a water
network, and this could explain the higher affinity of 4f for
Hp-SK than 4d, which has a CH2 group in the same position
(Fig. 4D and C, respectively).
Moreover, for ligands 5, the simulation studies revealed a
different behavior of both compounds, mainly relative to the
ether bridge. Thus, while for ligand 5R no significant confor-
mational changes were observed during the dynamic simu-
lation, this was not the case for ligand 5S. The ether bridge
moiety in 5S underwent a conformational change to locate the
Table 2 Ki (µM) values of compounds 2–5 against SK enzymes
a
Entry Comp R H. pylori M. tuberculosis
1 2 H 104 ± 4 62 ± 1 (ref. 13)
2 3 — 47 ± 6 46 ± 2 (ref. 13)
3 4a Me 54.5 ± 5.7 28 ± 1
4 4b Et 15.5 ± 1.1 41 ± 2
5 4c nPr 9.2 ± 1.0 72 ± 4
6 4d nBu 12 ± 2 177 ± 3
7 4e cPr 10.0 ± 0.6 101 ± 2
8 4f CH2OEt 5.0 ± 0.3 170 ± 3
9 4g CH2OBn 68 ± 3 121 ± 5
10 4h CH2OH 38 ± 3 333 ± 10
11 5S Me 465 ± 41 360 ± 7
12 5R Me ND 645 ± 16
a Assay conditions: Tris·HCl (100 mM, pH 7.7), ATP (2.5 mM), NADH
(0.2 mM), PEP (1 mM), MgCl2 (5 mM), KCl (100 mM), lactate dehydro-
genase/pyruvate kinase (∼2.8 units), 25 °C. For Mt-SK: Km (1) = 544 ±
14 µM; kcat = 295 ± 8 s
−1. For Hp-SK: Km (1) = 39 ± 8 µM; kcat = 116 ±
4 ms−1. ND = not determined.
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methyl group in parallel to the cyclohexene ring. This confor-
mation remained stable after ∼40 ns of simulation (Fig. S8†).
As a consequence, for both ligands 5, an interaction of the
methyl group with the carbon chain of the essential arginine
was not identified, as observed with compound 4f and pre-
viously reported saturated derivative 3. This fact revealed how
the rigidity of the ether bridge in the ligands would be crucial
to fix the position and direction of the substituent towards the
key residues of the lid.
In contrast to the above, for Mt-SK, as the length of the sub-
stituent increases (R = Et, nPr, nBu, CH2OEt) the ligands would
be located preferentially with the substituent pointing outside
the active site (Fig. 3G–H). In this arrangement, the introduc-
tion of this type of substituent in 2 would not contribute to an
improvement in ligand affinity since additional interactions
with the residues of the active site could not be established
(Fig. 4E–F).
For both enzymes, the substituent of the ligand interacts
with a similar region of the lid and this is quite similar in
terms of amino acid sequences. However, the results of the
computational studies revealed a clear and markedly distinct
induced fitting of the ligands by the two enzymes, which
would explain the differences found. These are due to key
differences in the folding of the lid over the active site – a situ-
ation that can be easily visualized by analysis of the vibrational
modes of the two enzymes (Fig. 5).19
Fig. 3 Binding mode of compounds 4a (green), 4c (cyan) and 4f (yellow) obtained by docking and MD simulation studies in the active site of the
Hp-SK (gray) and Mt-SK (dark blue) enzymes. A–C. Overall view of the Hp-SK/ATP/Mg2+/ligand complexes. Snapshots after 80 ns of simulation are
shown. Mg2+ (sphere) and ligands (sticks) and ATP (sticks) are displayed. D–F. Close view of ligands 4a, 4c and 4f in the SB binding pocket of Hp-SK.
Note how these ligands and the substituents of the ether bridge are perfectly surrounded by the enzyme, in particular for compounds 4c and 4f.
G–H. Close view of ligands 4a and 4f in the Mt-SK/ATP/Mg2+/ligand complexes. Note how for ligand 4f the substituent of the ether bridge would
not be embedded in the active site as for the H. pylori enzyme. I. Percentage of conformations of the ligands 4b–d and 4f during the 100 ns of simu-
lation in which the substituent of the ether bridge (Et, nPr, nBu, CH2OEt) would be located pointing towards the active site (inside).
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The functionalization of the double bond of previously identi-
fied scaffold 2, a stable mimetic of the high-energy confor-
mation of shikimic acid and a competitive reversible inhibitor
of the shikimate kinase enzyme, was carried out by ring-
closing metathesis of allyloxy vinyl derivatives 6 as the key
step. The latter compounds were prepared by Trost allylation
of previously reported alcohol 7 with allyl methyl carbonates 8.
The RCM approach required reaction temperatures of 90 °C
and the use of second-generation Grubbs’ catalyst.
The results obtained for the rigidified shikimic acid deriva-
tives reported, namely compounds 4–5, with the two enzymes
studied, SK from M. tuberculosis and from H. pylori, revealed
that: (i) the rigidification of the functionalized ether bridge
between C3 and C5 of the shikimic acid is crucial for improv-
ing ligand affinity; (ii) this functionalization generally provides
more potent analogs against the H. pylori enzyme than the
M. tuberculosis enzyme. A 20-fold improvement against the
H. pylori enzyme was achieved by the introduction of a CH2OEt
group in the rigid ether bridge of the reported shikimic acid
analogs. For the M. tuberculosis enzyme, the introduction of a
methyl group in 2 enhanced the ligand potency by a factor of
two.
Computational studies revealed that the differences in
affinity found with the two homologous enzymes are due to
the distinct induced-fit conformation adopted by the two
enzymes upon ligand binding, which mainly involves the sub-
strate-covering loop (lid). For Hp-SK, the substituents (R = Et,
nPr, nBu, CH2OEt) would be embedded in the active site, with
both the lid and the SB domain completely surrounding the
entire ligand. As a result, the active site would be neatly closed
because the ligands cause a dramatic reduction in the flexi-
bility of the lid and SB domain through a series of favorable
apolar interactions between the substituent and the residues
in this pocket. In contrast, for Mt-SK, as the length of the sub-
stituent increases (R = Et, nPr, nBu, CH2OEt) this moiety of the
ligand would be pointing away from the active site and there-
fore they would not contribute to an improvement in ligand
affinity. The results reported here can be considered as a good
example of how the rigidification of a ligand is a useful strat-
egy to enhance ligand affinity for a target due to the pre-orien-
tation and maximization of the interactions of its substituents.
Experimental
General
All starting materials and reagents were commercially available
and were used without further purification. 1H NMR spectra
(250, 300 and 500 MHz) and 13C NMR spectra (63, 75 and
125 MHz) were measured in deuterated solvents. J values are
given in hertz. NMR assignments were carried out by a combi-
nation of 1 D, COSY, and DEPT-135 experiments. FT-IR spectra
were recorded in a PerkinElmer two FTIR spectrometer with
attenuated total reference. [α]20D = values are given in 10
−1
deg cm2 g−1. MilliQ deionized water was used in all the
buffers. Melting points were measured in a Büchi M-560
apparatus. The experimental procedures for the synthesis of
carbonates 8 are described in the ESI.†
General procedure for synthesis of compounds 6
To a stirred solution of Pd2(dba)3 (0.025 mmol) and dppb
(0.1 mmol) in dry THF (0.8 mL), under argon and at room
temperature, were added the alcohol 7 13 (1 mmol), followed
by a solution of the carbonates 8a–g and 8i (1.5 mmol) in dry
THF (3 mL, 0.5 M). The resulting suspension was heated at
60 °C for 24 h and then cooled to room temperature. The
mixture was filtered over Celite® and the residue was washed
with diethyl ether. The filtrate and washings were evaporated
Fig. 4 Detailed view of the interactions of the ether bridge substituent
in 4a, 4c–d and 4f with Hp-SK (A–D) and in 4a and 4f with Mt-SK (E–F)
in their respective enzyme complexes. Relevant side chain residues are
shown and labeled. Apolar (magenta) and polar (blue) contacts are
shown as dashed lines. The interaction of the oxygen atom of the substi-
tuent in 4f with the amide main chain (carbonyl) of Val44 through a
water network is highlighted with blue shading.
Fig. 5 Overall view of the Hp-SK and Mt-SK motion obtained by exam-
ination of the vibrational modes. The motion of the lid is highlighted
with blue and yellow shading, respectively. Note how the folding of the
lid and as a consequence the essential arginine that it contains is quite
distinct in the two enzymes.
Organic Chemistry Frontiers Research Article
































































































under reduced pressure to yield an oil which was purified by
flash chromatography to afford the allyl ethers 6.
Methyl (3R,4S,5R)-5-(2-methyl)allyloxy-3,4-O-isopropyl-
idenedioxy-3-vinylcyclohex-1-ene-1-carboxylate (6a, R = Me). It
was prepared following the general allylation procedure using
7 (49 mg), Pd2(dba)3 (4.9 mg), dppb (8.1 mg), methyl-2-methyl-
allyl carbonate (8a)17 (30 mg) in dry THF (0.28 mL), THF
(0.8 mL). Eluent for chromatography = (30 : 70) diethyl ether/
hexane. Yield = 88% (52 mg). Colorless oil. [α]20D = +107.6°
(c 3.5, CHCl3).
1H NMR (300 MHz, CDCl3) δ: 6.64 (m, 1H, H2),
5.92 (dd, J = 17.3 and 10.7 Hz, 1H, CHvCH2), 5.44 (dd, J = 17.3
and 1.5 Hz, 1H, CHvCH2), 5.17 (dd, J = 10.7 and 1.5 Hz, 1H,
CHvCH2), 4.89 (d, J = 18.6 Hz, 2H, H3CCHvCH2), 4.09 (d, J =
4.0 Hz, 1H, H4), 4.02 (dd, J = 6.6 and 3.9 Hz, 1H, H5), 3.91 (d,
J = 5.3 Hz, 2H, CH2), 3.76 (s, 3H, OCH3), 2.64 (dd, J = 18.0 and
2.6 Hz, 1H, CHH-6), 2.44 (ddd, J = 18.0, 3.9 and 2.7 Hz, 1H,
CHH-6), 1.69 (s, 3H, CH3), 1.41 (s, 3H, CH3) and 1.34 (s, 3H,
CH3) ppm.
13C NMR (63 MHz, CDCl3) δ: 167.4 (C), 141.9 (C),
137.8 (C), 137.6 (C), 126.2 (C), 115.0 (CH2), 112.1 (CH2), 109.1
(C), 80.1 (C), 77.3 (CH), 73.3 (CH2), 73.2 (CH), 51.9 (CH), 27.9
(CH3), 26.9 (CH3), 24.3 (CH2) and 19.4 (CH3) ppm. FTIR (film)
ν: 1719 (CO) cm−1. MS (ESI) m/z = 331 (MNa+). HRMS calcd for
C17H24O5Na (MNa
+): 331.1516; found, 331.1511.
Methyl (3R,4S,5R)-5-(2-ethylallyloxy)-3,4-O-isopropyl-
idenedioxy-3-vinylcyclohex-1-ene-1-carboxylate (6b, R = Et). It
was prepared following the general allylation procedure using
7 (530 mg), Pd2(dba)3 (48 mg), dppb (89 mg), methyl (2-methyl-
enebutyl) carbonate (8b)17 (599 mg) in THF (8.3 mL), THF
(9 mL). Eluent for chromatography = (50 : 50) diethyl ether/
hexane. Yield = 32% (213 mg). It was recovered 221 mg of start-
ing material. Corrected yield = 74%. Colorless oil. [α]20D =
+99.1° (c 1.1, CHCl3).
1H NMR (300 MHz, CDCl3) δ: 6.64 (t, J =
1.3 Hz, 1H, H2), 5.92 (dd, J = 10.7 and 17.3 Hz, 1H, CHvCH2),
5.45 (dd, J = 1.5 and 17.3 Hz, 1H, CHvCHH), 5.18 (dd, J = 1.4
and 10.7 Hz, 1H, CHvCHH), 4.95 (m, 1H, CvCHH), 4.87 (m,
1H, CvCHH), 4.09 (m, 1H, H5), 4.02 (m, 1H, H4), 3.99 (d, J =
12.5 Hz, 1H, OCHH), 3.92 (d, J = 12.5 Hz, 1H, OCHH), 3.76 (s,
3H, OCH3), 2.65 (dd, J = 2.5 and 17.9 Hz, 1H, CHH-6), 2.44
(ddd, J = 2.8, 3.8 and 18.0 Hz, 1H, CHH-6), 2.02 (q, J = 7.4 Hz,
2H, CH2CH3), 1.42 (s, 3H, CH3), 1.34 (s, 3H, CH3) and 1.02 (t,
J = 7.4 Hz, 3H, CH2CH3) ppm.
13C NMR (63 MHz, CDCl3) δ:
167.5 (C), 147.5 (C), 137.9 (CH), 137.7 (CH), 126.3 (C), 115.1
(CH2), 110.3 (CH2), 109.1 (C), 80.2 (C), 77.3 (CH), 73.2 (CH),
72.5 (CH2), 52.0 (OCH3), 28.0 (CH3), 27.0 (CH3), 25.9 (CH2),
24.4 (CH2) and 12.0 (CH3) ppm. FTIR (film): 1710 (CO) cm
−1.
MS (ESI) m/z = 345 (MNa+). HRMS calcd for C18H26O5Na
(MNa+): 345.1672; found, 345.1681.
Methyl (3R,4S,5R)-3,4-O-isopropylidenedioxy-5-(2-propylally-
loxy)-3-vinylcyclohex-1-ene-1-carboxylate (6c, R = nPr). It was
prepared following the general allylation procedure using 7
(198 mg), Pd2(dba)3 (20 mg), dppb (33 mg), methyl (2-methyl-
enepentyl) carbonate (8c) (320 mg) in THF (2.3 mL), THF
(3 mL). Eluent for chromatography = (20 : 80) diethyl ether/
hexane. Yield = 47% (122 mg). Colorless oil. [α]20D = +92.8°
(c 1.1, CHCl3).
1H NMR (300 MHz, CDCl3) δ: 6.62 (t, J = 1.4 Hz,
1H, H2), 5.89 (dd, J = 10.7 and 17.4 Hz, 1H, CHvCH2), 5.42
(dd, J = 1.5 and 17.3 Hz, 1H, CHvCHH), 5.14 (dd, J = 1.5 and
10.7 Hz, 1H, CHvCHH), 4.93 (br s, 1H, CvCHH), 4.83 (br s,
1H, CvCHH), 4.06 (br d, J = 4.0 Hz, 1H, H4), 4.00 (td, J = 2.6
and 3.9 Hz, 1H, H5), 3.94 (d, J = 12.6 Hz, 1H, OCHH), 3.87 (d,
J = 12.6 Hz, 1H, OCHH), 3.73 (s, 3H, OCH3), 2.63 (dd, J = 2.6
and 18.0 Hz, 1H, CHH-6), 2.41 (ddd, J = 2.8, 3.8 and 18.0 Hz,
1H, CHH-6), 1.95 (t, J = 7.5 Hz, 2H, CH2CH3), 1.47–1.35 (m, 5H,
CH2 + CH3), 1.31 (s, 3H, CH3) and 0.86 (t, J = 7.3 Hz, 3H,
CH2CH3) ppm.
13C NMR (63 MHz, CDCl3) δ: 167.5 (C), 145.8
(C), 137.9 (CH), 137.7 (CH), 126.3 (C), 115.0 (CH2), 111.4 (CH2),
109.1 (C), 80.2 (C), 77.4 (CH), 73.3 (CH), 72.3 (CH2), 52.0
(OCH3), 35.2 (CH2), 28.0 (CH3), 27.0 (CH3), 24.4 (CH2), 20.8
(CH2) and 13.9 (CH3) ppm. FTIR (film): 1711 (CO) cm
−1. MS




loxy)-3-vinylcyclohex-1-ene-1-carboxylate (6d, R = nBu). It was
prepared following the general allylation procedure using 7
(373 mg), Pd2(dba)3 (38 mg), dppb (63 mg), methyl (2-methyl-
enehexyl) carbonate (8d) (380 mg) in THF (4.4 mL), THF
(6.4 mL). Eluent for chromatography = (10 : 90) diethyl ether/
hexane. Yield = 49% (250 mg). Colorless oil. [α]20D = 105.9°
(c 1.0, CHCl3).
1H NMR (300 MHz, CDCl3) δ: 6.64 (m, 1H, H2),
5.91 (dd, J = 10.7 and 17.3 Hz, 1H, CHvCH2), 5.44 (dd, J = 1.5
and 17.3 Hz, 1H, CHvCHH), 5.17 (dd, J = 1.5 and 10.7 Hz, 1H,
CHvCHH), 4.94 (m, 1H, CvCHH), 4.85 (m, 1H, CvCHH),
4.08 (td, J = 1.1 and 4.0 Hz, 1H, H4), 4.01 (dt, J = 2.5 and
3.8 Hz, 1H, H5), 3.96 (d, J = 12.8 Hz, 1H, OCHH), 3.89 (d, J =
12.8 Hz, 1H, OCHH), 3.75 (s, 3H, OCH3), 2.64 (m, 1H, CHH-6),
2.43 (ddd, J = 2.8, 3.8 and 18.0 Hz, 1H, CHH-6), 1.99 (t, J =
6.9 Hz, 2H, CH2(CH2)2CH3), 1.43–1.23 (m, 4H, CH2(CH2)2CH3),
1.41 (s, 3H, CH3), 1.33 (s, 3H, CH3) and 0.88 (t, J = 7.1 Hz, 3H,
CH2(CH2)2CH3) ppm.
13C NMR (63 MHz, CDCl3) δ: 167.5 (C),
146.1 (C), 137.9 (CH), 137.7 (CH), 126.3 (C), 115.0 (CH2), 111.2
(CH2), 109.1 (C), 80.2 (C), 77.3 (CH), 73.2 (CH), 72.4 (CH2), 52.0
(OCH3), 32.8 (CH2), 29.8 (CH2), 28.0 (CH3), 27.0 (CH3), 24.4
(CH2), 22.5 (CH2) and 14.0 (CH3) ppm. FTIR (film): 1717 (CO)
cm−1. MS (ESI) m/z = 373 (MNa+). HRMS calcd for C20H30O5Na
(MNa+): 373.1985; found, 373.1982.
Methyl (3R,4S,5R)-5-(2-cyclopropylmethylallyloxy)-3,4-O-iso-
propylidenedioxy-3-vinylcyclohex-1-ene-1-carboxylate (6e, R =
CH2cPr). It was prepared following the general allylation pro-
cedure using 7 (191 mg), Pd2(dba)3 (39 mg), dppb (64 mg),
2-(cyclopropylmethyl)allyl methyl carbonate (8e) (191 mg) in
THF (2.2 mL), THF (3 mL). Eluent for chromatography =
(20 : 80) diethyl ether/hexane. Yield = 34% (89 mg). Colorless
oil. [α]20D = +93.8° (c 1.0, CHCl3).
1H NMR (300 MHz, CDCl3)
δ: 6.64 (m, 1H, H2), 5.91 (dd, J = 10.7 and 17.3 Hz, 1H,
CHvCH2), 5.44 (dd, J = 1.4 and 17.3 Hz, 1H, CHvCHH), 5.18
(dd, J = 1.4 and 10.7 Hz, 1H, CHvCHH), 5.01 (br s, 1H,
CvCHH), 4.97 (br s, 1H, CvCHH), 4.07 (m, 1H, H5),
4.04–4.02 (m, 2H, H4 + OCHH), 3.95 (br d, J = 12.5 Hz, 1H,
OCHH), 3.76 (s, 3H, OCH3), 2.65 (dd, J = 2.5 and 18.0 Hz, 1H,
CHH-6), 2.44 (ddd, J = 2.8, 3.8 and 18.0 Hz, 1H, CHH-6), 1.90
(d, J = 6.8 Hz, 2H, CH2CH(CH2)2), 1.42 (s, 3H, CH3), 1.34 (s,
3H, CH3), 0.84–0.70 (m, 1H, CH2CH(CH2)2), 0.50–0.44 (m, 2H,
Research Article Organic Chemistry Frontiers
































































































CH2CHCH2CH2) and 0.08–0.03 (m, 2H, CH2CHCH2CH2) ppm.
13C NMR (75 MHz, CDCl3) δ: 167.6 (C), 146.1 (C), 138.0 (CH),
137.8 (CH), 126.4 (C), 115.2 (CH2), 111.6 (CH2), 109.2 (C),
80.3 (C), 77.5 (CH), 73.3 (CH), 72.6 (CH2), 52.1 (OCH3), 38.2
(CH2), 28.1 (CH3), 27.1 (CH3), 24.4 (CH2), 9.3 (CH), 4.8
(CH2) and 4.7 (CH2) ppm. FTIR (film): 1717 (CO) cm
−1. MS




pilidendioxi-3-vinylcyclohex-1-ene-1-carboxylate (6f, R =
CH2OEt). It was prepared following the general allylation pro-
cedure using 7 (255 mg), Pd2(dba)3 (26 mg), dppb (43 mg),
2-(ethoxymethyl)allyl methyl carbonate (8f ) (209 mg) in tetra-
hydrofuran (2.4 mL), tetrahydrofuran (4.3 mL). Eluent for
chromatography = (20 : 80) diethyl ether/hexane. Yield = 54%
(190 mg). Colorless oil. [α]20D = +85.2° (c 1.0, CHCl3).
1H NMR
(300 MHz, CDCl3) δ: 6.63 (t, J = 1.2 Hz, 1H, H2), 5.89 (dd, J =
10.7 and 17.3 Hz, 1H, CHvCH2), 5.43 (dd, J = 1.4 and 17.3 Hz,
1H, CHvCHH), 5.16 (dd, J = 1.4 and 10.7 Hz, 1H, CHvCHH),
5.12 (m, 2H, CvCH2), 4.08–3.96 (m, 4H, H4 + H5 + OCH2),
3.91 (br s, 2H, CH2OEt), 3.74 (s, 3H, OCH3), 3.44 (q, J = 7.0 Hz,
2H, OCH2CH3), 2.64 (dd, J = 2.5 and 18.0 Hz, 1H, CHH-6), 2.43
(ddd, J = 2.8, 3.7 and 18.0 Hz, 1H, CHH-6), 1.40 (s, 3H, CH3),
1.32 (s, 3H, CH3) and 1.18 (t, J = 7.0 Hz, 3H, OCH2CH3) ppm.
13C NMR (75 MHz, CDCl3) δ: 167.5 (C), 142.9 (C), 137.9 (CH),
137.7 (CH), 126.3 (C), 115.1 (CH2), 113.9 (CH2), 109.2 (C),
80.2 (C), 77.4 (CH), 73.7 (CH), 71.4 (CH2), 70.3 (CH2), 65.9 (CH2),
52.0 (OCH3), 28.0 (CH3), 27.0 (CH3), 24.5 (CH2) and 15.3 (CH3)
ppm. FTIR (film): 1716 (CO) cm−1. MS (ESI) m/z = 375 (MNa+).
HRMS calcd for C19H28O6Na (MNa
+): 375.1778; found, 375.1777.
Methyl (3R,4S,5R)-5-[(2-(benzyloxymethyl)allyloxy]-3,4-O-iso-
propilidendioxi-3-vinylcyclohex-1-ene-1-carboxylate (6g, R =
CH2OBn). It was prepared following the general allylation pro-
cedure using 7 (217 mg), Pd2(dba)3 (22 mg), dppb (37 mg),
2-(benzyloxymethyl)allyl methyl carbonate (8g) (242 mg) in
tetrahydrofuran (2.1 mL), tetrahydrofuran (3.7 mL). Eluent for
chromatography = (50 : 50) diethyl ether/hexane. Yield = 63%
(207 mg). Yellow oil. [α]20D = +85.9° (c 0.8, CHCl3).
1H NMR
(300 MHz, CDCl3) δ: 7.38–7.28 (m, 5H, 5 × ArH), 6.65 (t, J =
1.3 Hz, 1H, H2), 5.89 (dd, J = 10.7 and 17.3 Hz, 1H, CHvCH2),
5.43 (dd, J = 1.4 and 17.3 Hz, 1H, CHvCHH), 5.18–5.14 (m,
3H, CHvCHH + CvCH2), 4.49 (s, 2H, OCH2), 4.12–4.02 (m,
4H, H4 + H5 + CH2OBn), 3.99 (br s, 2H, OCH2Ph), 3.76 (s, 3H,
OCH3), 2.65 (dd, J = 2.5 and 18.0 Hz, 1H, CHH-6), 2.45 (ddd,
J = 2.8, 3.7 and 18.0 Hz, 1H, CHH-6), 1.42 (s, 3H, CH3) and
1.34 (s, 3H, CH3) ppm.
13C NMR (75 MHz, CDCl3) δ: 167.5 (C),
142.6 (C), 138.3 (C), 137.9 (CH), 137.7 (CH), 128.5 (2 × CH),
127.8 (2 × CH), 127.8 (CH), 126.3 (C), 115.2 (CH2), 114.3 (CH2),
109.2 (C), 80.2 (C), 77.4 (CH), 73.7 (CH), 72.3 (CH2), 70.9 (CH2),
70.3 (CH2), 52.0 (OCH3), 28.0 (CH3), 27.0 (CH3) and 24.5 (CH2)
ppm. FTIR (film): 1709 (CO) cm−1. MS (ESI) m/z = 437 (MNa+).





late (6i, R = CH2OTBS). It was prepared following the
general allylation procedure using 7 (96 mg), Pd2(dba)3
(10 mg), dppb (16 mg), 2-((tert-butyldimethylsilyloxy)methyl)
allyl methyl carbonate (8i) (118 mg) in THF (1 mL), THF
(1.6 mL). Eluent for chromatography = (25 : 75) diethyl ether/
hexane. Yield = 43% (72 mg). Colorless oil. [α]20D = +63.2° (c 1.0,
CHCl3).
1H NMR (250 MHz, CDCl3) δ: 6.63 (br s, 1H, H2), 5.89
(dd, J = 10.7 and 17.3 Hz, 1H, HCvCH2), 5.43 (dd, J = 1.4 and
17.3 Hz, 1H, HCvCHH), 5.18–5.14 (m, 2H, HCvCHH +
CvCHH), 5.04 (br s, 1H, CvCHH), 4.10 (br s, 2H, OCH2),
4.07–3.94 (m, 4H, H4 + H5 + CH2OTBS), 3.75 (s, 3H, OCH3),
2.63 (dd, J = 1.9 and 18.0 Hz, 1H, CHH-6), 2.42 (dt, J = 3.3 and
18.0 Hz, 1H, CHH-6), 1.40 (s, 3H, CH3), 1.33 (s, 3H, CH3), 0.89
(s, 9H, C(CH3)3) and 0.04 (s, 6H, 2 × CH3) ppm.
13C NMR
(63 MHz, CDCl3) δ: 167.5 (C), 145.0 (C), 137.9 (CH), 137.7 (CH),
126.3 (C), 115.2 (CH2), 112.0 (CH2), 109.2 (C), 80.2 (C), 77.3
(CH), 73.3 (CH), 70.2 (CH2), 63.9 (CH2), 52.1 (OCH3), 28.0
(CH3), 27.0 (CH3), 26.0 (C(CH3)3), 24.4 (CH2), 18.5 (C(CH3)3)
and −5.3 (2 × CH3) ppm. FTIR (film): 1716 (CO) cm−1. MS (ESI)
m/z = 461 (MNa+). HRMS calcd for C23H38O6SiNa (MNa
+):
461.2330; found, 461.2330.
General procedure for ring-closing metathesis of compounds
6a–g and 6i
A solution of compounds 6a–g and 6i (1 mmol) and 2nd gene-
ration Grubbs’ catalyst (0.02 mmol) in dry toluene (20 mM),
under an inert atmosphere, was heated at 90 °C for 24–48 h.
After cooling to room temperature, the mixture was filtered
over Celite® and the residue was washed with diethyl ether.
The filtrate and the washings were concentrated under
reduced pressure and purified by flash chromatography to
yield the bicycles 24a–g and 24i.
Methyl (1R,6S,10S)-6,10-O-isopropylidenedioxy-4-methyl-2-
oxabicyclo[4.3.1]deca-4(Z),7-diene-8-carboxylate (24a, R = Me).
It was prepared following the general RCM procedure using 6a
(100 mg), 2nd generation Grubbs’ catalyst (5.4 mg), toluene
(16 mL). Reaction time = 24 h. Eluent for chromatography =
(50 : 50) diethyl ether/hexane. Yield = 63% (57 mg). It was also
recovered 18 mg of starting material. Corrected yield = 77%.
Colorless oil. [α]20D = +11.4° (c 1.1, CHCl3).
1H NMR (300 MHz,
CDCl3) δ: 6.70 (q, J = 1.7 Hz, 1H, H7), 5.68 (t, J = 1.7 Hz, 1H,
H5), 4.50 (m, 1H, H1), 4.35 (dd, J = 5.0 and 1.7 Hz, 1H, H10),
4.28 (br d, J = 16.8 Hz, 1H, OCHH), 3.97 (d, J = 16.8 Hz, 1H,
OCHH), 3.72 (s, 3H, OCH3), 2.52 (m, 2H, CH2-9), 1.66 (s, 3H,
CH3), 1.39 (s, 3H, CH3) and 1.31 (s, 3H, CH3) ppm.
13C NMR
(75 MHz, CDCl3) δ: 167.6 (C), 140.0 (C), 138.0 (CH), 125.2 (C),
123.9 (CH), 110.1 (C), 79.8 (C), 75.0 (CH), 70.3 (CH), 68.0
(OCH2), 51.9 (OCH3), 28.1 (CH3), 27.3 (CH3), 27.3 (CH2) and
21.9 (CH3) ppm. FTIR (film): 1798 (CO) cm
−1. MS (ESI) m/z =




biciclo[4.3.1]deca-4(Z),7-diene-8-carboxylate (24b, R = Et). It
was prepared following the general RCM procedure using 6b
(190 mg), 2nd generation Grubbs’ catalyst (7 mg), toluene
(30 mL). Eluent for chromatography = (30 : 70) diethyl ether/
hexane. Reaction time = 48 h. Yield = 47% (82 mg). It was also
Organic Chemistry Frontiers Research Article
































































































recovered 95 mg of starting material. Corrected yield = 97%.
Colorless oil. [α]20D = +30.8° (c 1.0, CHCl3).
1H NMR (300 MHz,
CDCl3) δ: 6.67 (m, 1H, H7), 5.63 (m, 1H, H5), 4.46 (m, 1H, H1),
4.35–4.26 (m, 2H, H10 + OCHH-3), 3.99 (d, J = 16.6 Hz, 1H,
OCHH-3), 3.70 (m, 3H, OCH3), 2.51 (m, 2H, CH2-9), 1.93 (q, J =
7.4 Hz, 2H, CH2CH3), 1.37 (s, 3H, CH3), 1.30 (s, 3H, CH3) and
0.98 (t, J = 7.3 Hz, 3H, CH2CH3) ppm.
13C NMR (75 MHz,
CDCl3) δ: 167.5 (C), 145.4 (C), 138.0 (CH), 125.0 (C), 122.1
(CH), 110.0 (C), 80.0 (C), 75.0 (CH), 70.2 (CH), 67.3 (CH2), 51.9
(OCH3), 28.6 (CH2), 28.1 (CH3), 27.3 (CH3), 27.2 (CH2) and 12.0
(CH3) ppm. FTIR (film): 1712 (CO) cm
−1. MS (ESI) m/z = 317




oxabiciclo[4.3.1]deca-4(Z),7-diene-8-carboxylate (24c, R = nPr).
It was prepared following the general RCM procedure using 6c
(162 mg), 2nd generation Grubbs’ catalyst (6 mg), toluene
(24 mL). Eluent for chromatography = (20 : 80) diethyl ether/
hexane. Reaction time = 48 h. Yield = 63% (94 mg). It was also
recovered 43 mg of starting material. Corrected yield = 89%.
Colorless oil. [α]20D = +32.0° (c 1.0, CHCl3).
1H NMR (300 MHz,
CDCl3) δ: 6.69 (m, 1H, H7), 5.67 (m, 1H, H5), 4.48 (m, 1H, H1),
4.36 (dd, J = 1.6 and 6.6 Hz, 1H, H10), 4.29 (dd, J = 1.9 and
16.7 Hz, 1H, OCHH-3), 4.01 (d, J = 16.7 Hz, 1H, OCHH-3), 3.73
(m, 3H, OCH3), 2.53 (m, 2H, CH2-9), 1.92 (t, J = 7.5 Hz, 2H,
CH2CH2CH3), 1.44–1.36 (m, 5H, CH2CH2CH3 + CH3), 1.33 (s,
3H, CH3) and 0.88 (t, J = 7.3 Hz, 3H, (CH2)2CH3) ppm.
13C NMR (75 MHz, CDCl3) δ: 167.5 (C), 143.8 (C), 137.9 (CH),
125.0 (C), 123.3 (CH), 110.0 (C), 79.9 (C), 74.9 (CH), 70.2 (CH),
67.3 (CH2), 51.9 (OCH3), 38.0 (CH2), 28.1 (CH3), 27.2 (CH3),
27.2 (CH2), 20.8 (CH2) and 13.8 (CH3) ppm. FTIR (film):
1717 (CO) cm−1. MS (ESI) m/z = 331 (MNa+). HRMS calcd for
C17H24O5Na (MNa
+): 331.1516; found, 331.1513.
Methyl (1R,6S,10S)-4-butyl-6,10-O-isopropylidenedioxy-2-oxa-
biciclo[4.3.1]deca-4(Z),7-diene-8-carboxylate (24d, R = nBu). It
was prepared following the general RCM procedure using 6d
(110 mg), 2nd generation Grubbs’ catalyst (4 mg), toluene
(16 mL). Eluent for chromatography = (15 : 85) diethyl ether/
hexane. Reaction time = 24 h. Yield = 54% (54 mg). Colorless
oil. [α]20D = 37.5° (c 1.0, CHCl3).
1H NMR (300 MHz, CDCl3)
δ: 6.68 (m, 1H, H7), 5.65 (br s, 1H, H5), 4.47 (m, 1H, H1), 4.34
(dd, J = 1.7 and 5.0 Hz, 1H, H10), 4.29 (dd, J = 2.2 and 16.7 Hz,
1H, OCHH-3), 4.00 (d, J = 16.7 Hz, 1H, OCHH-3), 3.72 (m, 3H,
OCH3), 2.52 (m, 2H, CH2-9), 1.92 (t, J = 6.9 Hz, 2H,
CH2(CH2)2CH3), 1.38 (s, 3H, CH3), 1.36–1.21 (m, 4H,
CH2(CH2)2CH3), 1.31 (s, 3H, CH3) and 0.87 (t, J = 7.1 Hz, 3H,
(CH2)3CH3) ppm.
13C NMR (75 MHz, CDCl3) δ: 167.6 (C), 144.1
(C), 138.0 (CH), 125.0 (C), 123.1 (CH), 110.1 (C), 79.9 (C), 75.0
(CH), 70.2 (CH), 67.4 (CH2), 51.9 (OCH3), 35.7 (CH2), 29.8 (CH2),
28.1 (CH3), 27.3 (CH3), 27.2 (CH2), 22.5 (CH2) and 14.0 (CH3)
ppm. FTIR (film): 1717 (CO) cm−1. MS (ESI) m/z = 345 (MNa+).
HRMS calcd for C18H26O5Na (MNa
+): 345.1672; found, 345.1670.
Methyl (1R,6S,10S)-4-cyclopropylmethyl-6,10-O-isopropyl-
idenedioxy-2-oxabiciclo[4.3.1]deca-4(Z),7-diene-8-carboxylate
(24e, R = CH2cPr). It was prepared following the general RCM
procedure using 6e (105 mg), 2nd generation Grubbs’ catalyst
(19 mg), toluene (15 mL). Eluent for chromatography = (20 : 80)
diethyl ether/hexane. Reaction time = 48 h. Yield = 45%
(43 mg). It was also recovered 59 mg of starting material.
Corrected yield = quant. Colorless oil. [α]20D = +30.5° (c 1.1,
CHCl3).
1H NMR (300 MHz, CDCl3) δ: 6.69 (m, 1H, H7), 5.82
(m, 1H, H5), 4.48 (m, 1H, H1), 4.38–4.30 (m, 2H, H10 +
OCHH-3), 4.05 (d, J = 16.7 Hz, 1H, OCHH-3), 3.72 (m, 3H,
OCH3), 2.52 (m, 2H, CH2-9), 1.90 (dd, J = 6.4 and 15.8 Hz, 1H,
CHH), 1.77 (dd, J = 7.0 and 15.9 Hz, 1H, CHH), 1.40 (s, 3H,
CH3), 1.32 (s, 3H, CH3), 0.71 (m, 1H, CH2CH(CH2)2), 0.50–0.45
(m, 2H, CHCH2CH2) and 0.06–0.03 (m, 2H, CHCH2CH2) ppm.
13C NMR (75 MHz, CDCl3) δ: 167.6 (C), 144.0 (C), 138.1 (CH),
125.1 (C), 123.2 (CH), 110.1 (C), 80.0 (C), 75.0 (CH), 70.3 (CH),
67.4 (CH2), 52.0 (OCH3), 40.5 (CH2), 28.1 (CH3), 27.3 (CH3),
27.3 (CH3), 9.0 (CH), 4.8 (CH2) and 4.7 (CH2) ppm. FTIR (film):
1718 (CO) cm−1. MS (ESI) m/z = 343 (MNa+). HRMS calcd for
C18H24O5Na (MNa
+): 343.1516; found, 343.1524.
Methyl (1R,6S,10S)-4-(ethoxymethyl)-6,10-O-isopropyl-
idenedioxy-2-oxabiciclo[4.3.1]deca-4(Z),7-diene-8-carboxylate
(24f, R = CH2OEt). It was prepared following the general RCM
procedure using 6f (251 mg), 2nd generation Grubbs’ catalyst
(9 mg), toluene (23 mL). Reaction time = 48 h. Eluent for
chromatography = (20 : 80) diethyl ether/hexane. Yield = 16%
(36 mg). It was also recovered 156 mg of starting material.
Corrected yield = 78%. Yellow oil. [α]20D = +36.9° (c 1.0, CHCl3).
1H NMR (300 MHz, CDCl3) δ: 6.68 (m, 1H, H7), 5.95 (m, 1H,
H5), 4.51 (m, 1H, H1), 4.40 (dd, J = 1.4 and 4.8 Hz, 1H, H10),
4.32 (dd, J = 1.5 and 16.7 Hz, 1H, OCHH-3), 4.16 (d, J =
16.7 Hz, 1H, OCHH-3), 3.84 (sa, 2H, CH2OEt), 3.74 (s, 3H,
OCH3), 3.43 (q, J = 7.0 Hz, 1H, OCH2CH3), 2.55 (m, 2H, CH2-9),
1.40 (s, 3H, CH3), 1.33 (s, 3H, CH3) and 1.18 (t, J = 7.0 Hz, 3H,
CH3) ppm.
13C NMR (75 MHz, CDCl3) δ: 167.5 (C), 140.6 (C),
137.4 (CH), 125.9 (CH), 125.6 (C), 110.3 (C), 79.6 (C), 74.8 (CH),
73.1 (CH2), 70.3 (CH), 66.0 (CH2), 65.0 (CH2), 52.0 (OCH3), 28.1
(CH3), 27.3 (CH3), 27.2 (CH2) and 15.2 (CH3) ppm. FTIR (film):
1695 (CO) cm−1. MS (ESI) m/z = 347 (MNa+). HRMS calcd for
C17H24O6Na (MNa
+): 347.1465; found, 347.1466.
Preparation of 24f from 24i
A solution of the alcohol 24i (34 mg, 0.10 mmol) in dry DMF
(0.2 mL), at 0 °C and under argon, was treated with NaH
(6.6 mg, 0.17 mmol, ca. 60% w/w in mineral oil). After 30 min
stirring, bromoethane (20 μL, 0.17 mmol) was added, the ice
bath was removed and the reaction mixture was stirred for 3 h
at room temperature. The reaction mixture was diluted with a
mixture of (4 : 1) water/ethyl acetate, the organic layer was sep-
arated and the aqueous layer was extracted with ethyl acetate
keeping the same proportion. The combined organic extracts
were dried (anh. Na2SO4), filtered and concentrated under
reduced pressure. The resulting residue was purified by flash
chromatography, eluting with (50 : 50) ethyl acetate/hexane, to
give compound 24f (12 mg, 31%). It was also recovered 4 mg of
starting material. Corrected yield = 57%.
Methyl (1R,6S,10S)-4-(benzyloxymethyl)-6,10-O-isopropyl-
idenedioxy-2-oxabiciclo[4.3.1]deca-4(Z),7-diene-8-carboxylate
(24g, R = CH2OBn). It was prepared following the general RCM
Research Article Organic Chemistry Frontiers
































































































procedure using 6g (202 mg), 2nd generation Grubbs’ catalyst
(7 mg), toluene (27 mL). Reaction time = 48 h. Eluent for
chromatography = (20 : 80) diethyl ether/hexane. Yield = 26%
(53 mg). It was also recovered 138 mg of starting material.
Corrected yield = 94%. Yellow oil. [α]20D = +22.3° (c 1.0, CHCl3).
1H NMR (300 MHz, CDCl3) δ: 7.37–7.26 (m, 5H, 5 × ArH), 6.69
(m, 1H, H7), 5.98 (br s, 1H, H5), 4.51 (m, 1H, H1), 4.46 (s, 2H,
CH2Ph), 4.39 (dd, J = 1.5 and 4.8 Hz, 1H, H10), 4.33 (dd, J = 1.4
and 16.8 Hz, 1H, OCHH-3), 4.18 (d, J = 16.8 Hz, 1H, OCHH-3),
3.89 (sa, 2H, CH2OBn), 3.74 (s, 3H, OCH3), 2.55 (m, 2H, CH2-
9), 1.41 (s, 3H, CH3) and 1.34 (s, 3H, CH3) ppm.
13C NMR
(75 MHz, CDCl3) δ: 167.5 (C), 140.4 (C), 137.9 (C), 137.3 (CH),
128.6 (2 × CH), 127.9 (3 × CH), 126.5 (CH), 125.7 (C), 110.3 (C),
79.6 (C), 74.8 (CH), 72.6 (CH2), 72.5 (CH2), 70.3 (CH), 65.1
(CH2), 52.0 (OCH3), 28.1 (CH3), 27.3 (CH3) and 27.2 (CH2)
ppm. FTIR (film): 1716 (CO) cm−1. MS (ESI) m/z = 409 (MNa+).
HRMS calcd for C22H26O6Na (MNa
+): 409.1622; found,
409.1619.
Preparation of 24g from 24i
A solution of the alcohol 24i (31 mg, 0.10 mmol) in dry THF
(0.3 mL), at 0 °C and under argon, was treated with NaH
(6 mg, 0.15 mmol, ca. 60% w/w in mineral oil). After 30 min
stirring, benzyl bromide (20 μL, 0.15 mmol) was added, the ice
bath was removed and the reaction mixture was stirred for 3 h
at room temperature. Saturated NH4Cl was added, the organic
solvent was removed under reduced pressure and the aqueous
solution was extracted with ethyl acetate (×3). The combined
organic extracts were dried (anh. Na2SO4), filtered and concen-
trated under reduced pressure. The resulting residue was puri-
fied by flash chromatography, eluting with (25 : 75) ethyl
acetate/hexane, to give compound 24g (25 mg, 64%).
Methyl (1R,6S,10S)-4-((tert-butyldimethylsilyloxy)methyl)-
6,10-O-isopropylidenedioxy-2-oxabiciclo[4.3.1]deca-4(Z),7-diene-8-
carboxylate (24i, R = CH2OTBS). It was prepared following the
general RCM procedure using 6i (133 mg), 2nd generation
Grubbs’ catalyst (9 mg), toluene (15 mL). Reaction time = 48 h.
Eluent for chromatography = (20 : 80) diethyl ether/hexane.
Yield = 42% (52 mg). Colorless oil. [α]20D = +33.9° (c 1.0, CHCl3).
1H NMR (300 MHz, CDCl3) δ: 6.68 (m, 1H, H7), 5.92 (m, 1H,
H5), 4.51 (m, 1H, H1), 4.39 (dd, J = 1.6 and 4.8 Hz, 1H, H10),
4.28 (dd, J = 1.4 and 16.7 Hz, 1H, OCHH-3), 4.08 (d, J =
16.7 Hz, 1H, OCHH-3), 4.01 (dd, J = 1.3 and 4.6 Hz, 2H, CH2),
3.73 (s, 3H, OCH3), 2.54 (m, 2H, CH2-9), 1.40 (s, 3H, CH3), 1.33
(s, 3H, CH3), 0.89 (s, 9H, C(CH3)3), 0.05 (s, 3H, CH3) and 0.05
(s, 3H, CH3) ppm.
13C NMR (75 MHz, CDCl3) δ: 167.5 (C),
142.7 (C), 137.6 (CH), 125.4 (C), 123.3 (CH), 110.2 (C), 79.8 (C),
74.9 (CH), 70.3 (CH), 65.3 (CH2), 64.7 (CH2), 52.0 (OCH3), 28.1
(CH3), 27.2 (CH3), 27.2 (CH2), 26.0 (C(CH3)3), 18.5 (C(CH3)3),
−5.2 (CH3) and −5.2 (CH3) ppm. FTIR (film): 1716 (CO) cm−1.
MS (ESI) m/z = 433 (MNa+). HRMS calcd for C21H34O6SiNa
(MNa+): 433.2017; found, 433.2013.
Methyl (1R,6S,10S)-4-(hydroxymethyl)-6,10-O-isopropyl-
idenedioxy-2-oxabiciclo[4.3.1]deca-4(Z),7-diene-8-carboxylate
(24h, R = CH2OH). A solution of silyl ether 24i (53 mg,
0.13 mmol) in dry THF (1.3 mL), at 0 °C and under inert atmo-
sphere, was treated with TBAF (0.5 mL, ca. 1 M in THF). The
reaction mixture was stirred for 50 min and then diluted with
ethyl acetate. The organic solution was washed with water (×2),
NaHCO3 (sat) (×2), dried (anh. Na2SO4), filtered and concen-
trated under reduced pressure. The resulting residue was puri-
fied by flash chromatography, eluting with (50 : 50) diethyl
ether/hexane, to give the alcohol 24h (31 mg, 81%) as a color-
less oil. [α]20D = +37.1° (c 1.0, CHCl3).
1H NMR (300 MHz,
CDCl3) δ: 6.68 (d, J = 1.0 Hz, 1H, H7), 5.97 (br s, 1H, H5), 4.52
(m, 1H, H1), 4.40–4.32 (m, 2H, H10 + OCHH-3), 4.18 (d, J =
16.7 Hz, 1H, OCHH), 4.02 (t, J = 4.3 Hz, 2H, CH2), 3.74 (s, 3H,
OCH3), 2.55 (m, 2H, CH2-9), 1.40 (s, 3H, CH3) and 1.34 (s, 3H,
CH3) ppm.
13C NMR (75 MHz, CDCl3) δ: 167.3 (C), 142.9 (C),
137.2 (CH), 125.5 (C), 124.4 (CH), 110.2 (C), 79.5 (C), 74.6 (CH),
70.2 (CH), 65.0 (CH2), 64.5 (CH2), 51.9 (CH3), 28.0 (CH3), 27.1
(CH3) and 27.0 (CH2) ppm. FTIR (film): 3441 (OH) and 1709
(CO) cm−1. MS (ESI) m/z = 319 (MNa+). HRMS calcd for
C15H20O6Na (MNa
+): 319.1152; found, 319.1152.
General procedure for the acetal deprotection in 24a–h
A solution of the acetals 24a–h (1 mmol) in methanol (7 mL)
and aqueous HCl (8.6 mL, 6 M) was heated at 60 °C for 6 h.
The mixture was cooled and concentrated under reduced
pressure. The residue was purified by flash chromatography to
yield the diols 25a–h.
Methyl (1R,6S,10S)-6,10-dihydroxy-4-methyl-2-oxabicyclo
[4.3.1]deca-4(Z),7-diene-8-carboxylate (25a, R = Me). It was pre-
pared following the general deprotection procedure using 24a
(39 mg), HCl (0.2 mL) and methanol (1 mL). Eluent for chrom-
atography = (50 : 50) ethyl acetate/hexane. Yield = 88% (30 mg).
Colorless oil. [α]20D = −86.6° (c 3.0, CH3OH).
1H NMR (300 MHz,
CD3OD) δ: 6.64 (m, 1H, H7), 5.46 (m, 1H, H5), 4.25 (m, 2H,
H1 + OCHH), 4.12 (dd, J = 4.9 and 1.6 Hz, 1H, H10), 3.85 (d, J =
16.5 Hz, 1H, OCHH), 2.59 (dt, J = 17.9 and 2.9 Hz, 1H, CHH-9),
2.28 (dd, J = 17.9 and 2.3 Hz, 1H, CHH-9) and 1.68 (s, 3H, CH3)
ppm. 13C NMR (75 MHz, CD3OD) δ: 168.3 (C), 144.0 (CH),
140.2 (C), 139.9 (CH), 129.4 (C), 128.7 (CH), 75.4 (CH), 72.6 (C),
70.6 (CH), 67.5 (CH2), 28.3 (CH2) and 22.2 (CH3) ppm. FTIR
(ATR): 3416 (OH) and 1698 (CO) cm−1. MS (ESI) m/z = 263




deca-4(Z),7-diene-8-carboxylate (25b, R = Et). It was prepared
following the general deprotection procedure using 24b
(128 mg), HCl (0.7 mL) and methanol (2.9 mL). Eluent for
chromatography = ethyl acetate. Yield = 91% (99 mg). Colorless
oil. 1H NMR (300 MHz, CDCl3) δ: 6.69 (m, 1H, H7), 5.47 (dd,
J = 1.6 and 3.5 Hz, 1H, H5), 4.33 (quint, J = 2.6 Hz, 1H, H1),
4.21–4.15 (m, 2H, H10 + OCHH-3), 3.92 (d, J = 16.4 Hz, 1H,
OCHH-3), 3.72 (s, 3H, OCH3), 3.00 (br s, 2H, 2 × OH), 2.61 (td,
J = 2.9 and 18.3 Hz, 1H, CHH-9), 2.40 (dd, J = 2.0 and 18.3 Hz,
1H, CHH-9), 1.97 (qd, J = 1.2 and 7.4 Hz, 2H, CH2CH3) and
0.98 (t, J = 7.4 Hz, 3H, CH3) ppm.
13C NMR (63 MHz, CDCl3)
δ: 167.8 (C), 145.3 (C), 138.8 (CH), 127.4 (C), 125.7 (CH), 73.3
(CH), 72.0 (C), 69.8 (CH), 66.3 (CH2), 52.1 (OCH3), 29.0 (CH2),
27.2 (CH2) and 12.2 (CH3) ppm. FTIR (film): 3395 (OH) and
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1701 (CO) cm−1. MS (ESI) m/z = 277 (MNa+). HRMS calcd for
C13H18O5Na (MNa
+): 277.1046; found, 277.1044.
Methyl (1R,6S,10S)-6,10-dihydroxy-4-propyl-2-oxabicyclo
[4.3.1]deca-4(Z),7-diene-8-carboxylate (25c, R = nPr). It was pre-
pared following the general deprotection procedure using 24c
(122 mg), HCl (0.7 mL) and methanol (2.6 mL). Reaction
time = 18 h. Eluent for chromatography = (80 : 20) diethyl
ether/hexane. Yield = 80% (87 mg). Colorless oil. [α]20D = −48.1°
(c 1.0, CHCl3).
1H NMR (300 MHz, CDCl3) δ: 6.69 (br s, 1H,
H7), 5.48 (d, J = 1.4 Hz, 1H, H5), 4.32 (m, 1H, H1), 4.20–4.14
(m, 2H, H10 + OCHH-3), 3.93 (d, J = 16.4 Hz, 1H, OCHH-3),
3.72 (m, 3H, OCH3), 3.07 (br s, 2H, 2 × OH), 2.61 (dt, J = 2.9
and 18.3 Hz, 1H, CHH-9), 2.40 (dd, J = 1.7 and 18.2 Hz, 1H,
CHH-9), 1.93 (t, J = 7.4 Hz, 2H, CH2CH2CH3), 1.38 (m, 2H,
CH2CH2CH3) and 0.87 (t, J = 7.3 Hz, 3H, (CH2)2CH3) ppm.
13C
NMR (75 MHz, CDCl3) δ: 167.8 (C), 143.6 (C), 138.8 (CH), 127.3
(C), 127.0 (CH), 73.3 (CH), 72.0 (C), 69.7 (CH), 66.2 (CH2), 52.0
(OCH3), 38.6 (CH2), 27.2 (CH2), 21.0 (CH2) and 13.8 (CH3)
ppm. FTIR (film): 3412 (OH) and 1700 (CO) cm−1. MS (ESI)




deca-4(Z),7-diene-8-carboxylate (25d, R = nBu). It was prepared
following the general deprotection procedure using 24d
(124 mg), HCl (0.7 mL) and methanol (3 mL). Reaction time =
6 h. Eluent for chromatography = (90 : 10) diethyl ether/
hexane. Yield = 89% (95 mg). Colorless oil. [α]20D = −42.3°
(c 1.0, CH3OH).
1H NMR (300 MHz, CD3OD) δ: 6.68 (br s, 1H,
H7), 5.48 (br s, 1H, H5), 4.31–4.26 (m, 2H, H1 + OCHH-3), 4.16
(br d, J = 4.8 Hz, 1H, H10), 3.94 (d, J = 16.3 Hz, 1H, OCHH-3),
3.77 (s, 3H, OCH3), 2.63 (td, J = 2.8 and 18.0 Hz, 1H, CHH-9),
2.32 (br d, J = 18.5 Hz, 1H, CHH-9), 2.02 (t, J = 6.5 Hz, 2H,
CH2(CH2)2CH3), 1.44–1.34 (m, 4H, CH2(CH2)2CH3) and 0.95 (t,
J = 6.8 Hz, 3H, (CH2)3CH3) ppm.
13C NMR (75 MHz, CD3OD)
δ: 169.2 (C), 144.1 (C), 140.9 (CH), 128.9 (CH), 127.8 (C), 75.1
(CH), 72.5 (C), 70.5 (CH), 66.8 (CH2), 52.3 (OCH3), 37.2 (CH2),
31.1 (CH2), 28.2 (CH2), 23.3 (CH2) and 14.3 (CH3) ppm. FTIR
(film): 3419 (OH) and 1710 (CO) cm−1. MS (ESI) m/z = 305




oxabicyclo[4.3.1]deca-4(Z),7-diene-8-carboxylate (25e, R =
CH2cPr). It was prepared following the general deprotection
procedure using 24e (160 mg), HCl (0.8 mL) and methanol
(3.3 mL). Reaction time = 18 h. Eluent for chromatography =
(90 : 10) diethyl ether/hexane. Yield = 76% (107 mg). White
solid. [α]20D = −44.4° (c 1.0, CHCl3). Mp: 128.2–128.7 °C.
1H
NMR (300 MHz, CDCl3) δ: 6.74 (m, 1H, H7), 5.66 (m, 1H, H5),
4.38 (m, 1H, H1), 4.28–4.22 (m, 2H, OCHH-3 + H10), 4.01 (d,
J = 16.4 Hz, 1H, OCHH-3), 3.74 (s, 3H, OCH3), 2.65 (dt, J = 3.0
and 18.3 Hz, 1H, CHH-9), 2.45 (dd, J = 2.1 and 18.3 Hz, 1H,
CHH-9), 1.88 (m, 2H, CH2), 0.78–0.65 (m, 1H, CH2CH(CH2)2),
0.52–0.46 (m, 2H, CHCH2CH2), 0.07 (dd, J = 1.3 and 5.0 Hz,
1H, CHCH2CHH) and 0.04 (dd, J = 1.4 and 4.7 Hz, 1H,
CHCH2CHH) ppm.
13C NMR (75 MHz, CDCl3) δ: 167.8 (C),
143.7 (C), 138.8 (CH), 127.3 (C), 126.8 (CH), 73.3 (CH), 72.0 (C),
69.7 (CH), 66.3 (CH2), 52.0 (OCH3), 41.0 (CH2), 27.2 (CH2), 9.1
(CH), 4.8 (CH2) and 4.7 (CH2) ppm. FTIR (film): 3393 (OH) and
1685 (CO) cm−1. MS (ESI) m/z = 303 (MNa+). HRMS calcd for
C15H20O5Na (MNa
+): 303.1203; found, 303.1200.
Methyl (1R,6S,10S)-4-ethoxymethyl-6,10-dihydroxy-2-oxabicy-
clo[4.3.1]deca-4(Z),7-diene-8-carboxylate (25f, R = CH2OEt). It
was prepared following the general deprotection procedure
using 24f (49 mg), HCl (0.3 mL) and methanol (1 mL).
Reaction time = 11 h. Eluent for chromatography = (70 : 30)
ethyl acetate/hexane. Yield = 80% (34 mg). Brown oil. [α]20D =
−35.1° (c 1.0, CHCl3). 1H NMR (300 MHz, CDCl3) δ: 6.70 (br s,
1H, H7), 5.77 (br s, 1H, H5), 4.38 (q, J = 2.3 Hz, 1H, H1),
4.24–4.19 (m, 2H, H10 + OCHH-3), 4.08 (d, J = 16.5 Hz, 1H,
OCHH-3), 3.85 (br s, 2H, CH2OEt), 3.74 (s, 3H, OCH3), 3.44 (q,
J = 7.0 Hz, 2H, OCH2CH3), 2.65 (dt, J = 2.9 and 18.4 Hz, 1H,
CHH-9), 2.45 (br d, J = 17.9 Hz, 1H, CHH-9) and 1.18 (t, J = 7.0
Hz, 3H, OCH2CH3) ppm.
13C NMR (75 MHz, CDCl3) δ:
167.6 (C), 140.2 (C), 138.1 (CH), 129.7 (CH), 127.9 (C), 73.5
(CH), 73.4 (CH2), 71.8 (C), 69.6 (CH), 66.1 (CH2), 64.0 (CH2),
52.1 (OCH3), 27.2 (CH2) and 15.2 (CH3) ppm. FTIR (film):
3406 (OH) and 1709 (CO) cm−1. MS (ESI) m/z = 307 (MNa+).




bicyclo[4.3.1]deca-4(Z),7-diene-8-carboxylate (25g, R = OBn). It
was prepared following the general deprotection procedure
using 24g (55 mg), HCl (0.2 mL) and methanol (0.9 mL).
Reaction time = 12 h. Eluent for chromatography = diethyl
ether. Yield = 85% (41 mg). Colorless oil. [α]20D = −24.2° (c 1.0,
MeOH). 1H NMR (300 MHz, CD3OD) δ: 7.39–7.27 (m, 5H, 5 ×
ArH), 6.69 (m, 1H, H7), 5.77 (m, 1H, H5), 4.48 (br s, 2H,
CH2Ph), 4.33–4.27 (m, 2H, H1 + OCHH-3), 4.20 (dd, J = 1.4 and
4.9 Hz, 1H, H10), 4.08 (d, J = 16.4 Hz, 1H, OCHH-3), 3.94 (s,
2H, CH2OBn), 3.76 (s, 3H, OCH3), 2.65 (dt, J = 2.9 and 18.1 Hz,
1H, CHH-9) and 2.28 (m, 1H, CHH-9) ppm. 13C NMR (75 MHz,
CD3OD) δ: 169.2 (C), 140.6 (C), 140.3 (CH), 139.4 (C), 132.3
(CH), 129.4 (2 × CH), 129.0 (2 × CH), 128.7 (CH), 128.4 (C), 75.3
(CH), 73.8 (CH2), 73.0 (CH2), 72.4 (C), 70.3 (CH), 64.6 (CH2),
52.3 (OCH3) and 28.2 (CH2) ppm. FTIR (film): 3406 (OH) and
1709 (CO) cm−1. MS (ESI) m/z = 369 (MNa+). HRMS calcd for
C19H22O6Na (MNa
+): 369.1309; found, 369.1307.
Methyl (1R,6S,10S)-4-hydroxymethyl-6,10-dihydroxy-2-oxabi-
cyclo[4.3.1]deca-4(Z),7-diene-8-carboxylate (25i, R = CH2OH). It
was prepared following the general deprotection procedure
using 24i (81 mg), HCl (0.3 mL) and methanol (1.8 mL).
Reaction time = 8 h. Eluent for chromatography = ethyl
acetate. Yield = 95% (66 mg). Colorless oil. [α]20D = −147.5°
(c 0.8, MeOH). 1H NMR (300 MHz, CD3OD) δ: 6.65 (br s, 1H,
H7), 5.69 (br s, 1H, H5), 4.29–4.24 (m, 2H, H1 + OCHH-3), 4.16
(m, 1H, H10), 4.01 (d, J = 16.4 Hz, 1H, OCHH-3), 3.95 (d, J =
13.5 Hz, 1H, CHH-OH), 3.89 (d, J = 13.5 Hz, 1H, CHH-OH),
3.72 (s, 3H, OCH3), 2.60 (dt, J = 2.8 and 18.0 Hz, 1H, CHH-9)
and 2.29 (d, J = 18.0 Hz, 1H, CHH-9) ppm. 13C NMR (75 MHz,
CD3OD) δ: 169.2 (C), 143.4 (C), 140.5 (CH), 129.6 (CH), 128.2
(C), 75.2 (CH), 72.4 (C), 70.3 (CH), 65.5 (CH2), 64.4 (CH2), 52.3
(OCH3) and 28.2 (CH2) ppm. FTIR (film): 3372 (OH) and 1697
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(CO) cm−1. MS (ESI) m/z = 279 (MNa+). HRMS calcd for
C12H16O6Na (MNa
+): 279.0839; found, 279.0838.
General procedure for the ester hydrolysis in 25a–h
A solution of the esters 25a–h (1 mmol) in THF (10 mL) was
treated at room temperature with an aqueous solution of LiOH
(1.2 mL, 2.5 M). After stirring for 1 h, water was added and
THF was removed under reduced pressure. The aqueous layer
was washed with ethyl acetate (×3) and then treated with
Amberlite IR-120 (H+) until pH 6. The resin was filtered off and
washed with MilliQ water. The filtrate and the washings were
lyophilized to give acids 4.
(1R,6S,10S)-6,10-Dihydroxy-4-methyl-2-oxabicyclo[4.3.1]deca-
4(Z),7-diene-8-carboxylic acid (4a, R = Me). It was prepared fol-
lowing the general basic hydrolysis procedure using 25a
(230 mg), LiOH (0.14 mL) and THF (1.2 mL). Yield = 86%
(25 mg). White solid. Mp: 216 °C (dec.). [α]20D = −52° (c 2.5,
CH3OH).
1H NMR (300 MHz, CD3OD) δ: 6.63 (br s, 1H, H7),
5.47 (m, 1H, H5), 4.27–4.22 (m, 2H, H1 + OCHH), 4.12 (dd, J =
4.9 and 1.5 Hz, H10), 3.85 (d, J = 16.4 Hz, 1H, OCHH), 2.28 (dt,
J = 18.0 and 2.8 Hz, 1H, CHH-9), 2.28 (dd, J = 18.0 and 2.0 Hz,
1H, CHH-9) and 1.68 (s, 3H, CH3) ppm.
13C NMR (75 MHz,
CD3OD) δ: 171.2 (C), 140.2 (CH), 139.9 (C), 129.4 (CH), 128.7
(C), 75.3 (CH), 72.6 (C), 70.6 (CH), 67.5 (CH2), 28.3 (CH2) and
22.2 (CH3) ppm. FTIR (ATR): 3325 (OH) and 1637 (CO) cm
−1.
MS (ESI) m/z = 225 (M − H). HRMS calcd for C11H13O5
(M − H): 225.0768; found, 225.0764.
(1R,6S,10S)-4-Ethyl-6,10-dihydroxy-2-oxabicyclo[4.3.1]deca-4
(Z),7-diene-8-carboxylic acid (4b, R = Et). It was prepared fol-
lowing the general basic hydrolysis procedure using 25b
(39 mg), LiOH (0.18 mL) and THF (1.5 mL). Yield = 99%
(35 mg). White solid. Mp: 216 °C (dec.). [α]20D = −24.7° (c 1.0,
MeOH). 1H NMR (300 MHz, D2O) δ: 6.57 (s, 1H, H7), 5.36 (m,
1H, H5), 4.23–4.17 (m, 2H, H1 + OCHH), 4.07 (dd, J = 1.2 and
4.8 Hz, 1H, H10), 3.81 (d, J = 16.4 Hz, 1H, OCHH), 2.49 (dt, J =
2.8 and 18.1 Hz, 1H, CHH-9), 2.18 (dd, J = 1.3 and 18.0 Hz, 1H,
CHH-9), 1.89 (q, J = 7.4 Hz, 2H, CH2) and 0.91 (t, J = 7.4 Hz,
3H, CH3) ppm.
13C NMR (75 MHz, D2O) δ: 170.8 (C), 145.5 (C),
140.8 (CH), 128.1 (C), 127.8 (CH), 75.2 (CH), 72.6 (C), 70.4
(CH), 66.8 (CH2), 29.9 (CH2), 28.2 (CH2) and 12.7 (CH3) ppm.
FTIR (film): 3365 (OH) and 1688 (CO) cm−1. MS (ESI) m/z = 240
(M − H). HRMS calcd for C12H15O5 (M − H): 239.0925; found,
239.0921.
(1R,6S,10S)-6,10-Dihydroxy-4-propyl-2-oxabicyclo[4.3.1]deca-
4(Z),7-diene-8-carboxylic acid (4c, R = nPr). It was prepared fol-
lowing the general basic hydrolysis procedure using 25c
(58 mg), LiOH (0.9 mL) and THF (2.2 mL). Yield = 99%
(55 mg). White foam. [α]20D = −38.1° (c 1.0, H2O).
1H NMR
(300 MHz, D2O) δ: 6.72 (br s, 1H, H7), 5.47 (br s, 1H, H5),
4.38–4.27 (m, 3H, H1 + H10 + OCHH-3), 3.93 (d, J = 16.6 Hz,
1H, OCHH-3), 2.56 (br d, J = 18.6 Hz, 1H, CHH-9), 2.29 (d, J =
18.5 Hz, 1H, CHH-9), 1.95 (t, J = 7.2 Hz, 2H, CH2CH2CH3), 1.35
(m, 2H, CH2CH2CH3) and 0.82 (t, J = 7.3 Hz, 3H, (CH2)2CH3)
ppm. 13C NMR (75 MHz, D2O) δ: 173.2 (C), 146.4 (C), 141.9
(CH), 129.6 (C), 129.1 (CH), 75.8 (CH), 74.3 (C), 71.1 (CH), 68.0
(CH2), 40.4 (CH2), 29.2 (CH2), 22.9 (CH2) and 15.4 (CH3) ppm.
FTIR (film): 3392 (OH) and 1688 (CO) cm−1. MS (ESI) m/z = 253
(M − H). HRMS calcd for C13H17O5 (M − H): 253.1081; found,
253.1081.
(1R,6S,10S)-4-Butyl-6,10-dihydroxy-2-oxabicyclo[4.3.1]deca-4
(Z),7-diene-8-carboxylic acid (4d, R = nBu). It was prepared fol-
lowing the general basic hydrolysis procedure using 25d
(87 mg), LiOH (1.2 mL) and THF (3 mL). Yield = 98% (82 mg).
White solid. Mp: 129.1–131.0 °C. [α]20D = −20.3° (c 1.0, H2O).
1H
NMR (300 MHz, D2O) δ: 6.52 (br s, 1H, H7), 5.47 (br s, 1H, H5),
4.39–4.32 (m, 2H, H1 + OCHH-3), 4.25 (dd, J = 1.8 and 5.0 Hz,
1H, H10), 3.93 (br d, J = 16.5 Hz, 1H, OCHH-3), 2.57 (td, J = 3.0
and 18.6 Hz, 1H, CHH-9), 2.26 (br d, J = 18.8 Hz, 1H, CHH-9),
1.98 (t, J = 6.8 Hz, 2H, CH2(CH2)2CH3), 1.36–1.18 (m, 4H,
CH2(CH2)2CH3) and 0.83 (t, J = 7.1 Hz, 3H, (CH2)3CH3) ppm.
13C NMR (75 MHz, D2O) δ: 172.7 (C), 143.1 (C), 136.6 (CH),
129.5 (C), 127.0 (CH), 73.3 (CH), 71.8 (C), 68.7 (CH), 65.3
(CH2), 35.6 (CH2), 29.3 (CH2), 27.2 (CH2), 21.7 (CH2) and 13.2
(CH3) ppm. FTIR (film): 3367 (OH) and 1691 (CO) cm
−1. MS
(ESI) m/z = 267 (M − H). HRMS calcd for C14H19O5 (M − H):
267.1238; found, 267.1235.
(1R,6S,10S)-4-Cyclopropylmethyl-6,10-dihydroxy-2-oxabicyclo
[4.3.1]deca-4(Z),7-diene-8-carboxylic acid (4e, R = CH2cPr). It
was prepared following the general basic hydrolysis procedure
using 25e (44 mg), LiOH (0.5 mL) and THF (1.4 mL). Yield =
99% (37 mg). White foam. [α]20D = −14.8° (c 1.0, H2O).
1H NMR
(300 MHz, D2O) δ: 6.43 (m, 1H, H7), 5.62 (m, 1H, H5),
4.42–4.36 (m, 2H, H1 + OCHH-3), 4.26 (dd, J = 1.6 and 4.9 Hz,
1H, H10), 3.98 (d, J = 16.5 Hz, 1H, OCHH-3), 2.57 (td, J = 2.9
and 18.7 Hz, 1H, CHH-9), 2.27 (d, J = 18.5 Hz, 1H, CHH-9),
1.87 (d, J = 6.8 Hz, 2H, CH2), 0.73 (m, 1H, CH2CH(CH2)2),
0.48–0.42 (m, 2H, CHCH2CH2) and 0.04 (m, 2H, CH2) ppm.
13C
NMR (75 MHz, D2O) δ: 174.3 (C), 143.1 (C), 134.7 (CH), 131.3
(C), 126.9 (CH), 73.5 (CH), 72.0 (C), 68.7 (CH), 65.5 (CH2), 40.1
(CH2), 27.6 (CH2), 8.5 (CH), 3.8 (CH2) and 3.7 (CH2) ppm. FTIR
(film): 3286 (OH) and 1680 (CO) cm−1. MS (ESI) m/z = 265 (M −
H). HRMS calcd for C14H17O5 (M − H): 265.1081; found, 265.1079.
(1R,6S,10S)-4-Ethoxymethyl-6,10-dihydroxy-2-oxabicyclo[4.3.1]
deca-4(Z),7-diene-8-carboxylic acid (4f, R = CH2OEt). It was pre-
pared following the general basic hydrolysis procedure using
25f (39 mg), LiOH (0.6 mL) and THF (1.4 mL). Reaction time =
30 min. Yield = 45% (17 mg). White foam. [α]20D = −18.0° (c 1.0,
H2O).
1H NMR (300 MHz, D2O) δ: 6.71 (br s, 1H, H7), 5.82 (br
s, 1H, H5), 4.45 (m, 1H, H1), 4.35 (m, 2H, H10 + OCHH-3),
4.07 (d, J = 16.5 Hz, 1H, OCHH-3), 3.96 (s, 2H, CH2OEt), 3.53
(q, J = 7.0 Hz, 2H, OCH2CH3), 2.65 (dt, J = 2.6 and 18.8 Hz, 1H,
CHH-9), 2.36 (br d, J = 18.5 Hz, 1H, CHH-9) and 1.18 (t, J =
7.0 Hz, 3H, OCH2CH3) ppm.
13C NMR (75 MHz, D2O) δ: 171.0
(C), 139.0 (C), 137.7 (CH), 130.7 (CH), 128.4 (C), 73.4 (CH), 72.4
(CH2), 71.5 (C), 68.2 (CH), 65.5 (CH2), 63.3 (CH2), 26.6 (CH2)
and 14.0 (CH3) ppm. FTIR (film): 3361 (OH) and 1689 (CO)
cm−1. MS (ESI) m/z = 269 (M − H). HRMS calcd for C13H17O6
(M − H): 269.1031; found, 269.1030.
(1R,6S,10S)-4-Benzyloxymethyl-6,10-dihydroxy-2-oxabicyclo
[4.3.1]deca-4(Z),7-diene-8-carboxylic acid (4g, R = CH2OBn). It
was prepared following the general basic hydrolysis procedure
using 25g (58 mg), LiOH (0.7 mL) and THF (1.7 mL). Reaction
Organic Chemistry Frontiers Research Article
































































































time = 4 h. Yield = 99% (56 mg). White solid. Mp: 186 °C
(dec.). [α]20D = −5.5° (c 1.0, H2O).
1H NMR (300 MHz, D2O) δ:
7.38 (m, 5H, 5 × ArH), 6.35 (br s, 1H, H7), 5.80 (br s, 1H, H5),
4.48 (br s, 2H, CH2Ph), 4.37 (m, 1H, H1), 4.29 (d, J = 16.5 Hz,
1H, OCHH-3), 4.23 (d, J = 4.3 Hz, 1H, H10), 4.02 (d, J = 16.5 Hz,
1H, OCHH-3), 3.97 (br s, 2H, CH2OBn), 2.59 (dt, J = 2.7 and
18.7 Hz, 1H, CHH-9) and 2.28 (d, J = 18.5 Hz, 1H, CHH-9) ppm.
13C NMR (75 MHz, D2O) δ: 175.0 (C), 137.8 (C), 137.1 (C), 133.1
(C), 132.7 (CH), 132.2 (CH), 128.6 (2 × CH), 128.5 (2 × CH),
128.2 (CH), 73.7 (CH), 72.5 (CH2), 71.8 (C), 71.6 (CH2), 68.4
(CH), 63.1 (CH2) and 27.7 (CH2) ppm. FTIR (film): 3286 (OH)
and 1681 (CO) cm−1. MS (ESI) m/z = 331 (M − H). HRMS calcd
for C18H19O6 (M − H): 331.1187; found, 331.1185.
C14H17O5 (M − H): 265.1081; found, 265.1079.
(1R,6S,10S)-4-Hydroxylmethyl-6,10-dihydroxy-2-oxabicyclo
[4.3.1]deca-4(Z),7-diene-8-carboxylic acid (4h, R = CH2OH). It
was prepared following the general basic hydrolysis procedure
using 25h (58 mg), LiOH (0.9 mL) and THF (2.3 mL). Reaction
time = 8 h. Yield = 99% (55 mg). White solid. Mp:
117.3–119.2 °C. [α]20D = −28.1° (c 1.0, H2O).
1H NMR (300 MHz,
D2O) δ: 6.36 (br s, 1H, H7), 5.59 (br s, 1H, H5), 4.26–4.19 (m,
2H, H1 + OCHH-3), 4.14 (m, 1H, H10), 3.89–3.77 (m, 3H,
OCHH-3 + CH2OH), 2.45 (dt, J = 2.8 and 18.8 Hz, 1H, CHH-9)
and 2.15 (br d, J = 18.6 Hz, 1H, CHH-9) ppm. 13C NMR
(75 MHz, D2O) δ: 175.4 (C), 143.8 (C), 138.2 (CH), 132.8 (C),
131.0 (CH), 76.1 (CH), 74.2 (C), 70.9 (CH), 66.4 (CH2), 65.6
(CH2) and 29.7 (CH2) ppm. FTIR (film): 3349 (OH) and 1688
(CO) cm−1. MS (ESI) m/z = 241 (M − H). HRMS calcd for
C11H13O6 (M − H): 241.0718; found, 241.0719.
(1R,4S,6S,10S)-(5S) and (1R,4R,6S,10S)-6,10-dihydroxy-4-
methyl-2-oxabicyclo[4.3.1]dec-7-ene-8-carboxylic acid (5R). A
suspension of the alkene 25a (57 mg, 0.20 mmol), Rosenmund
catalyst (10 mg, 5 wt% loading) and a few drops of pyridine in
methanol (5 mL) was shaken under a hydrogen atmosphere at
room temperature for 7 h. The mixture was filtered over
Celite® and the residue was washed with methanol. The fil-
trate and washings were evaporated under reduced pressure. A
solution of the resulting oil (63 mg) in ethanol (1.5 mL) and
aqueous HCl (0.4 mL, 6 M) was heated at 60 °C for 6 h. The
mixture was cooled and concentrated under reduced pressure.
A solution of the resulting oil (50 mg) in THF (2 mL) was
treated at room temperature with an aqueous solution of LiOH
(1.3 mL, 0.63 mmol, 0.5 M). After stirring for 4 h, water was
added and THF was removed under reduced pressure. The
aqueous layer was washed with ethyl acetate (×3) and it was
then treated with Amberlite IR-120 (H+) until pH 6. The resin
was filtered off and washed with milliQ water. The filtrate and
the washings were lyophilized to give acids 5S and 5R (48 mg,
99%) as a mixture of epimers in C4. Both compounds were
separated by HPLC using semipreparative column
(Phenomenex Luna5u, 250 × 10 mm, C18), eluting with a gra-
dient of acetonitrile–water [(1) 0–5 min (5 : 95 → 10 : 90)
CH3CN/H2O; (2) 5–20 min (10 : 90 → 20 : 80) CH3CN/H2O], at a
flow rate of 3.5 mL min−1.
Data for 5R. Yield = 45%. Retention time: 16.2 min. Mp:
192.1–193.2 °C. [α]20D = +7° (c 0.5, H2O).
1H NMR (500 MHz,
D2O) δ: 6.70 (br s, 1H, H7), 4.42 (m, 1H, H1), 4.24 (m, 1H,
H10), 3.56 (dd, J = 12.9 and 10.1 Hz, 1H, OCHH), 3.47 (m, 1H,
OCHH), 2.56 (dt, J = 18.3 and 3.0 Hz, 1H, CHH-9), 2.26 (dd, J =
18.1 and 2.0 Hz, 1H, CHH-9), 2.02 (ddd, J = 12.9, 4.3 and
1.6 Hz, 1H, CHH-5), 1.66–1.58 (m, 1H, H4), 1.43 (t, J = 12.9 Hz,
1H, CHH-5) and 0.83 (d, J = 6.9 Hz, 3H, CH3) ppm.
13C NMR
(100 MHz, D2O) δ: 170.5 (C), 140.5 (CH), 129.2 (C), 73.4 (CH),
71.4 (C), 69.3 (OCH2), 68.7 (CH), 45.3 (CH2), 31.4 (CH), 27.2
(CH2) and 16.8 (CH3) ppm. FTIR (ATR): 3376 (OH) and 1686
(CO) cm−1. MS (ESI) m/z = 227 (M − H). HRMS calcd for
C11H15O5 (M − H): 227.0925; found, 227.0922.
Data for 5S. Yield = 45%. Retention time: 16.6 min. Mp:
179.4–180.9 °C. [α]20D = −22° (c 0.6, H2O).
1H NMR (500 MHz,
D2O) δ: 6.77 (br s, 1H, H7), 4.36 (dt, J = 4.0 and 1.9 Hz, 1H,
H1), 4.23 (dd, J = 4.6 and 1.7 Hz, 1H, H10), 3.82 (dd, J = 13.0
and 3.0 Hz, 1H, CHH-3), 3.42 (dd, J = 13.0 and 5.5 Hz, 1H,
CHH-3), 2.62 (ddd, J = 18.9, 4.0 and 2.8 Hz, 1H, CHH-9),
2.32 (d, J = 18.9 Hz, 1H, CHH-9), 2.10–2.04 (m, 1H, H4), 1.96
(dd, J = 14.3 and 6.4 Hz, 1H, CHH-5), 1.81 (dd, J = 14.3 and
5.9 Hz, 1H, CHH-5) and 0.91 (d, J = 7.2 Hz, 3H, CH3) ppm.
13C NMR (100 MHz, D2O) δ: 170.5 (C), 142.8 (CH), 127.9 (C),
73.1 (CH), 71.5 (C), 69.3 (CH), 67.6 (OCH2), 42.8 (CH2), 30.9
(CH), 26.7 (CH2) and 18.5 (CH3) ppm. FTIR (ATR): 3396
(OH) and 1690 (CO) cm−1. MS (ESI) m/z = 227 (M − H).
HRMS calcd for C11H15O5 (M − H): 227.0925; found,
227.0928.
Docking studies
They were carried out using the GOLD 5.2.2 program and the
enzyme coordinates found in the crystal structures of Hp-SK in
complex with shikimate-3-phosphate and ADP (PDB entry
3MUF,15 2.3 Å) and of Mt-SK in complex with 2 and ADP (PDB
entry 4BQS,13 2.15 Å). Ligand geometries were minimized
using the AM1 Hamiltonian as implemented in the program
Gaussian 09 20 and used as MOL2 files. Each ligand was
docked in 25 independent genetic algorithm (GA) runs, and
for each of these a maximum number of 100 000 GA operations
were performed on a single population of 50 individuals.
Operator weights for crossover, mutation and migration in the
entry box were used as default parameters (95, 95, and 10,
respectively), as well as the hydrogen bonding (4.0 Å) and van
der Waals (2.5 Å) parameters. The position of shikimate-3-
phosphate and compound 2 present in the aforementioned
PDB files were used to define the active-site and the radius was
set to 8 Å. All crystallographic water molecules and the afore-
mentioned ligands were removed for docking. The “flip ring
corners” flag was switched on, while all the other flags were
off. The GOLD scoring function was used to rank the ligands
in order to fitness. The molecular graphics program PyMOL
was employed for visualization and depicting ligand/protein
structures.21
Molecular dynamics simulation studies
Ligand minimization. Ligand geometries were minimized
using a restricted Hartree–Fock (RHF) method and a 6-31G(d)
basis set, as implemented in the ab initio program Gaussian
Research Article Organic Chemistry Frontiers
































































































09. The resulting wavefunctions were used to calculate electro-
static potential-derived (ESP) charges employing the restrained
electrostatic potential (RESP)22 methodology, as implemented
in the assisted model building with energy refinement
(AMBER)23 suite of programs. The missing bonded and non-
bonded parameters were assigned, by analogy or through
interpolation, from those already present in the AMBER data-
base (GAFF).20,24
Generation and minimization of ternary complexes.
Simulations of SK/ATP/Mg2+/ligand complexes were carried out
using the highest score solution obtained by docking and the
enzyme geometries used in those docking studies, as
described above. Computation of the protonation state of titra-
table groups at pH 7.0 was carried out using the H++ Web
server.25 Addition of hydrogen and molecular mechanics para-
meters from the ff14SB and GAFF force fields, respectively,
were assigned to the protein and the ligands using the LEaP
module of AMBER Tools 17.26,27 ATP and Mg2+ parameters
used with the AMBER force field were included.28,29 All
systems were minimized in four stages: (a) initial minimiz-
ation of the ligand and the closest residues of the SB domain
(500 steps, first half using steepest descent and the rest using
conjugate gradient); (b) minimization of the solvent and ions
(5000 steps, first half using steepest descent and the rest using
conjugate gradient); (c) minimization of the side chains,
waters and ions (5000 steps, first half using steepest descent
and the rest using conjugate gradient); (d) final minimization
of the whole system (5000 steps, first half using steepest
descent and the rest using conjugate gradient). A positional
restraint force of 50 kcal mol−1 Å−2 was applied to those un-
minimized atoms during the first three stages (a–c). The
complex was immersed in a truncated octahedron of ∼5200
TIP3P water molecules and neutralized by addition of chloride
(Mt-SK) or sodium (Hp-SK) ions.30,31
Simulations. MD simulations were performed using the
pmemd.cuda_SPFP32 module from the AMBER 16 suite of pro-
grams. Periodic boundary conditions were applied and electro-
static interactions were treated using the smooth particle mesh
Ewald method (PME)33 with a grid spacing of 1 Å. The cutoff
distance for the non-bonded interactions was 9 Å. The SHAKE
algorithm34 was applied to all bonds containing hydrogen,
using a tolerance of 10−5 Å and an integration step of 2.0 fs.
The minimized system was then heated at 300 K at 1 atm by
increasing the temperature from 0 K to 300 K over 100 ps and
by keeping the system at 300 K another 100 ps. A positional
restraint force of 50 kcal mol−1 Å−2 was applied to all α
carbons during the heating stage. An equilibration of the
system at constant volume (100 ps with positional restraints of
5 kcal mol−1 Å−2 to α alpha carbons) and constant pressure
(another 100 ps with positional restraints of 5 kcal mol−1 Å−2
to α alpha carbons) were performed. The positional restraints
were gradually reduced from 5 to 1 mol−1 Å−2 (5 steps, 100 ps
each), and the resulting systems were allowed to equilibrate
further (100 ps). Unrestrained MD simulations were carried




Hp-SK Shikimate kinase from Helicobacter pylori
Mt-SK Shikimate kinase from Mycobacterium tuberculosis
MD Molecular dynamics
PDB Protein data bank
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